Pharmaron Beijing Finalizes Equity Disposal Deal

Pharmaron Beijing Co., Ltd. Class H (HK:3759) has released an update.

Pharmaron Beijing Co., Ltd. has successfully completed the disposal of its equity interests in Proteologix, with its subsidiary Pharmaron (Hong Kong) Investments Limited receiving an initial payment of US$86.195 million post-transaction adjustments. The company confirms that additional milestone payments are anticipated upon the achievement of specific targets as per the Merger Agreement. This strategic move signifies a pivotal financial development for the stakeholders of Pharmaron Beijing.

For further insights into HK:3759 stock, check out TipRanks’ Stock Analysis page.